Ethical considerations in industry-sponsored Multiregional Clinical Trials

被引:7
|
作者
Ibia, Ekopimo [1 ]
Binkowitz, Bruce [1 ]
Saillot, Jean-Louis [1 ]
Talerico, Steven [1 ]
Koerner, Chin [2 ]
Ferreira, Irene [3 ]
Agarwal, Anupam [4 ]
Metz, Craig [4 ]
Maman, Marianne [2 ]
机构
[1] Merck & Co Inc, Whitehouse Stn, NJ USA
[2] Novartis Pharmaceut, Rockville, MD USA
[3] Amgen Inc, Cambridge, Cambs, England
[4] GlaxoSmithKline Plc, Collegeville, PA USA
关键词
ethical principles; Multiregional Clinical Trials; global trials; post-trial benefits; informed consent process; data monitoring; DEVELOPING-COUNTRIES; GLOBALIZATION;
D O I
10.1002/pst.458
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
During the last several decades, the scientific and ethics communities have addressed important ethical issues in medical research, resulting in the elaboration and adoption of concepts, guidelines, and codes. Ethical issues in the conduct of Multiregional Clinical Trials have attracted significant attention mainly in the last two decades. With the globalization of clinical research and the rapid expansion to countries with a limited tradition of biomedical research, sponsors must proactively address local ethical issues, the adequacy of oversight as well as the applicability and validity of data, and scientific conclusions drawn from diverse patient populations. This paper highlights some core ethical principles and milestones in medical research, and, from an industry perspective, it discusses ethical issues that the clinical trial team may face when conducting Multiregional Clinical Trials (MRCT, clinical trials conducted at sites located across multiple geographic regions of the world). This paper further highlights the areas of consensus and controversies and proposes points to consider. Copyright (C) 2010 John Wiley & Sons, Ltd.
引用
收藏
页码:230 / 241
页数:12
相关论文
共 50 条
  • [1] Ethical assessment of industry-sponsored clinical trials - A case analysis
    Miller, FG
    Shorr, AF
    [J]. CHEST, 2002, 121 (04) : 1337 - 1342
  • [2] Industry-sponsored clinical trials: time to publication
    Mathias, Marla
    LaFlamme, K. Elizabeth
    Johnson, Tracy H.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 : S12 - S12
  • [3] Budget negotiation for industry-sponsored clinical trials
    Beal, K
    Dean, J
    Chen, J
    Dragaon, E
    Saulino, A
    Collard, CD
    [J]. ANESTHESIA AND ANALGESIA, 2004, 99 (01): : 173 - 176
  • [4] Industry-sponsored clinical trials and medical publishing
    N. J. C. Snell
    [J]. International Journal of Pharmaceutical Medicine, 2001, 15 (5): : 217 - 218
  • [5] Ethical considerations of industry-sponsored research: The use of human subjects
    Moreno, JD
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 1996, 15 (05) : S35 - S40
  • [6] Development of an authorship algorithm for industry-sponsored clinical trials
    Fusaro, Gina
    Matheis, Robert
    Weigel, Al
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 : S13 - S13
  • [7] Recent trends and controversies in industry-sponsored clinical trials
    Reed, CR
    Camargo, CA
    [J]. ACADEMIC EMERGENCY MEDICINE, 1999, 6 (08) : 833 - 839
  • [8] Emergency medicine leadership in industry-sponsored clinical trials
    Newgard, CD
    Kim, S
    Camargo, CA
    [J]. ACADEMIC EMERGENCY MEDICINE, 2003, 10 (02) : 169 - 174
  • [9] Mitigating Administrative Risks in Industry-sponsored Clinical Trials
    Kim, Paul J.
    [J]. JOURNAL OF FOOT & ANKLE SURGERY, 2011, 50 (06): : 633 - 634
  • [10] Medical journals, academia, and industry-sponsored clinical trials
    Frighi, V
    [J]. PLOS MEDICINE, 2005, 2 (07) : 686 - 686